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Introduction
Publication of this report from the Committee on Tech-
nologies for the Early Detection of Breast Cancer, chaired
by JC Lashof and I Craig Henderson (vice chair), is timely
and important. The Institute of Medicine Committee
assembled a 16-member interdisciplinary group, and the
contributions included in the book reflect this wide-angle
approach to the problem. Each specialist may find less
than he or she would like, but I found many interesting
details that are useful for gaining a general understanding
of the technological future of breast cancer screening.
Imaging technology is examined within the context of the
complex natural history of breast cancer; advances in
current understanding of genetic and biological issues,
and in therapeutic approaches are less briefly, but exhaus-
tively, presented.
Emerging technologies
Following a short presentation of the history of mammo-
graphy, the theory of efficacy evaluation through random-
ized clinical trials (all referenced) and the more recent
evaluations of screening programmes that are ongoing in
several countries are critically re-examined. The second
chapter discusses new developments in breast imaging
and in related technologies; a table presents the current
status of imaging technologies for a large number of
devices, few of which are currently of interest with regard
to early detection. Most of the technologies discussed
pertain to clinical diagnosis, and are unlikely to surpass
mammography in the field of early detection in the near
future.
A chapter entitled Technologies in development: genetic
and tumor markers reports on the progress that has been
made in this important field, but it states that “… the ability
to predict who will develop breast cancer is modest at
best.” We are still in the realm of basic research, and
application of these technologies in screening is far from
reaching routine daily practice. However, the authors
emphasize the opportunity to improve predictive oncology
in the early stages of breast cancer. Furthermore, with
private companies developing genetic tests, and the fact
that “The tests are not subject to FDA [Food and Drug
Administration] regulation and thus clinical validity and
utility did not have to be documented before entry into the
market”, there is a need for a new policy and for genetic
counselling for women who request testing.
The following chapter on the development and regulation
of new technologies (which is referred to only within the
context of the USA) is original to the best of my knowl-
edge, at least for a European audience. The narrative of
the initiatives and collaborations that have been active
between government agencies, private industries and
associations, and the examples of funding mechanisms for
medical technology development confirm the massive
investment into breast cancer care in recent years. The US
FDA regulation process for the approval of technologies is
well described in relation to the approval of imaging and
laboratory devices. Core to this book is an understanding
of how the approval process of screening devices by a
regulatory agency, and clinical outcome evaluations
should be related.
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Efficiency evaluation of novel technologies
The last chapters deal with evaluation of efficiency and
policy issues. In this context the cost coverage of tech-
nologies by insurance agencies (e.g. Medicare and Medic-
aid in the USA) is discussed, as are the implications for
dissemination of their use to large populations. Technol-
ogy assessment is not subject to approval by the FDA,
and the report here poses two questions. First, can the
technology positively impact on patient outcomes?
Second, how does the technology compare with other
technologies that are on the market?
The role of evidence-based research is growing to
address these questions, and both randomized clinical
trials and nonexperimental studies are briefly presented.
The role of meta-analysis and overview of the existing
research is also considered. The conclusion supports the
concept of large surveillance studies to evaluate the effec-
tiveness of technologies in clinical practice. The Breast
Cancer Surveillance Consortium, established by the US
National Cancer Institute in 1994, is an original and impor-
tant initiative that was initiated to evaluate population-
based screening mammography in the USA. It covers a
large population, and it is expected to contribute to
research and technology assessments.
Finally, the use and availability of screening mammogra-
phy is presented, with specific reference to the US health
system. Guidelines, information and promotion, access to
the service, and training and reimbursement are briefly
discussed.
The Executive Summary
Without questioning the efficacy of mammography, the
Executive Summary looks at how the development of this
technology may inform the development and assessment
of emerging imaging technologies. What can we learn
from the history of the evaluation of mammography in
order to assess the efficacy of other screening technolo-
gies? Also, how should we adapt our assessment of new
approaches in the light of future technological advances?
In recent years imaging technologies for early detection of
breast cancer have improved relative to traditional
imaging, but such development has mainly had conse-
quences for facilitating storage, transmission and compari-
son in order to improve diagnostic accuracy. However, the
question remains as to what extent these new technolo-
gies (sometimes with substantial incremental costs) will
impact on our ability to detect cancers early in terms of
better outcomes. The change could be a positive one, in
terms of better outcomes, but it could also be negative
(higher costs, over-diagnosis and over-treatment). The
most difficult question remains; how can we assess the
incremental benefit and the possible adverse effects of
early diagnosis?
Biomolecular technologies, such as markers of suscepti-
bility, present similar problems with evaluation to those of
imaging technologies; success should be measured in
terms of better prevention strategies, and not just greater
knowledge. The dominant framework for regulation and
evaluation of medical technologies has historically been
based on therapeutics: detection technologies are not
assessed in the same way, and as such their evaluation is
not regulated at all.
The long and controversial history of mammography
should not be considered as a paradigm for future tech-
nology evaluation. The history and controversies that have
arisen in medical and lay journals should inform future
guidelines for early detection assessment. It is quite
remarkable that screening by Pap smear for cervical
cancer, which was criticized because it was introduced as
a screening modality in the absence of any demonstration
of efficacy, is now more readily accepted than mammogra-
phy, which has been subjected to the most rigorous exper-
imental evaluation. Conclusions from empirical studies
have been shown to be prone to subjective interpretations
and prejudices.
The report recommends that, for new screening technolo-
gies, “approval by the FDA and coverage decisions …
should depend on evidence of improved clinical outcome”
at an early stage in the evaluation process. Attempts to
detect early evidence of improved outcome surrogates for
decreased disease-specific mortality may be appropriate,
although rigorous research into these surrogates is
required.
Acceptance of these recommendations will radically
change the evaluation of screening modalities and diag-
nostic devices. It has recently been suggested that guide-
lines developed for early detection devices may also be
used to assess biomarkers [1]. In the book preliminary
(unpublished) work from Gatsonis is reported, and he sug-
gests phases of the process of evaluation that are compa-
rable to those used for drugs. More work and debate is
needed on these topics, and the process of evaluating
new screening technologies should represent an occasion
for implementation of guidelines in the field of early detec-
tion assessment.
Conclusion
As Lashof points out, many issues, especially knowledge
of the natural biological history of the disease, need a
large and interdisciplinary research effort, and much
remains to be done to improve our early-stage detection
technologies. The contributions that this book makes to
development of better and more comprehensive
processes for the evaluation of early detection devices,
and to establishing rules for the approval of early detection
technologies by governmental agencies are certainlyworthy of consideration by scientists who are interested in
breast cancer research.
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